Northlane Capital Partners Invests in Forensic Testing Leader
Northlane Capital Partners (NCP) has made a significant move in the healthcare sector by investing in United States Drug Testing Laboratories Inc. (USDTL). This partnership aims to enhance the capabilities of USDTL, a prominent forensic toxicology lab specializing in alcohol and substance testing, establishing a solid foundation of support for growth.
A Strategic Partnership
NCP’s investment is made in partnership with USDTL's management and founders, Veronica and Doug Lewis. This collaboration marks a new chapter for USDTL, providing the company with the resources and expertise required to propel its operations forward. With NCP's backing, USDTL is set to reach new heights in its mission to provide accurate and reliable drug testing services.
Insights into USDTL’s Operations
Headquartered in Des Plaines, IL, USDTL offers an extensive range of forensic testing services that cater to various clients, including hospitals, health systems, court systems, and employers. This diverse clientele underscores USDTL's critical role in the forensic testing landscape. With a dedicated team of over 160 employees and a robust customer base exceeding 1,000, USDTL has established itself as a leader in the industry.
Expert Leadership Driving Growth
In line with this investment, USDTL has appointed Albert Berger as its new Chief Executive Officer. With more than 20 years of expertise in forensic toxicology and laboratory management, including previous CEO roles at Confirm Biosciences and Redwood Toxicology, Mr. Berger brings a wealth of experience to USDTL. His leadership will be pivotal as the company embarks on its next phase of expansion.
Veronica Lewis’s Vision for USDTL
As a founder of USDTL, Veronica Lewis expressed enthusiasm about the partnership with NCP, indicating the investment is a crucial milestone for the company. Having dedicated three decades to building USDTL, she welcomes NCP as an institutional partner that aligns well with the company's vision and operational goals. Veronica emphasized NCP's extensive experience in laboratory services, highlighting the potential for collaborative growth.
Justin DuFour on the Partnership
Justin DuFour, a Partner at NCP, also shared his insights on this partnership. He remarked on USDTL’s longstanding position as an innovator in specialized forensic testing over the past 30 years. DuFour looks forward to leveraging NCP's expansive network and expertise to implement value-creating initiatives and enhance USDTL’s unique testing capabilities.
NCP’s Focus on Healthcare Investments
Northlane Capital Partners, based in Bethesda, MD, has firmly cemented its place within the healthcare and business services sectors. With more than $1.7 billion of equity capital invested, NCP remains committed to partnering with leading companies and exceptional management teams. The foundational strategy of the firm centers on aligning incentives to foster growth and drive value in the industries it engages.
Looking to the Future
As NCP and USDTL forge ahead, they are poised to explore new opportunities within the forensic testing market. With NCP’s financial strength and operational support combined with USDTL's established reputation, the future looks bright for both entities. This collaboration signifies a promising evolution in their ability to meet the growing demands for forensic testing services.
Frequently Asked Questions
What is the nature of Northlane Capital Partners' investment?
Northlane Capital Partners has invested in United States Drug Testing Laboratories to enhance its forensic testing capabilities and support its expansion.
Who are the founders of United States Drug Testing Laboratories?
The founders of USDTL are Veronica and Doug Lewis, who have played significant roles in establishing the company’s operations.
What services does USDTL offer?
USDTL provides a broad suite of forensic testing services primarily focusing on alcohol and substance use testing.
How many employees does USDTL have?
USDTL employs over 160 individuals, highlighting the company’s significant operational scale in the forensic testing sector.
What is NCP's investment strategy?
NCP focuses on partnering with industry-leading companies in healthcare and business services, aligning incentives to catalyze growth and value creation.
